Efforts to promote safer opioid prescribing in Canada appear to be having an effect, as new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250670 shows a decrease in opioid dispensing between 2018 and… read more.
Insmed announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of its DPP1 inhibitor Brinsupri (brensocatib… read more.
A prospective population-based cohort study of suboptimally active adults (<8,000 steps per day) assessed whether individuals who accumulate their daily steps in shorter or longer bouts are at… read more.
In ongoing efforts to pinpoint the best evidence-based ways to quit smoking, a University of Massachusetts Amherst public health researcher has turned her attention to a tobacco-free product… read more.
Teva Pharmaceutical Industries Ltd. entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue (trastuzumab), a biosimilar to Herceptin, across a majority of European markets…. read more.
Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according… read more.
The federal Food and Drug Administration today approved a new menopause drug that reduces hot flashes and night sweats after the drug was successfully tested at UVA Health… read more.
Pfizer Inc and Astellas announced final overall survival (OS) results from the Phase III EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as monotherapy, in men with… read more.
The electronic health record data analysed in this study is anonymised and never leaves a secure data environment, which is only accessible by approved researchers working on approved… read more.
Compiled by the Generation Green task force, the textbook builds on the original Finnish version and explores the environmental consequences of medicine production, use, and disposal, including pharmaceutical residues in… read more.
KalVista Pharmaceuticals, Inc. announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual… read more.
Boehringer Ingelheim’s Jascayd (nerandomilast) has been approved by China’s National Medical Products Administration (NMPA) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients. This… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
